![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Guidance Links Cost-Effectiveness of Osteoporosis Treatments with Fracture Risk
NICE Guidance Links Cost-Effectiveness of Osteoporosis Treatments with Fracture Risk
August 14, 2017
New guidance from the UK’s National Institute of Health and Care Excellence links the cost-effectiveness of different bisphosphonate medications for osteoporosis with a patient’s 10-year risk of bone fractures.
NICE recommended beginning treatment with oral alendronic acid, ibandronic acid or risedronate sodium in individuals with at least a 1 percent risk of fracture over a decade. Intravenous ibandronic acid and zoledronic acid is recommended for those with at least a 10 percent risk.
Clinical trial results showed Olumiant plus conventional disease-modifying antirheumatic drugs were more effective than conventional treatments alone for severe RA, according to NICE.
Upcoming Events
-
21Oct